PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1455605
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1455605
The Asia-Pacific pharmacogenetics testing in psychiatry/depression market is expected to reach USD 478.26 thousand by 2031 from USD 202.98 thousand in 2023, growing with a CAGR of 11.5% in the forecast period of 2024 to 2034.
Asia-Pacific Pharmacogenetics Testing in Psychiatry/Depression Market, By Type (Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders), Test Type (Whole Genome Sequencing and Chromosomal Array-Based Tests), Patient Type (Child, Adults, and Geriatric), Gene Type (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and Others), Products (Instruments, Consumables, and Software and Services), End User (Hospitals and Clinics, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distribution, Hospital Pharmacy, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031